Oncology perioperative expansion: Imfinzi wins a conditional public-funding nod in gastric/GEJ
A reimburse-with-conditions recommendation for a durvalumab regimen in resectable gastric cancer extends an immunotherapy franchise into the perioperative setting — and the conditions attached are where the channel economics actually get decided.
In April 2026, CDA-AMC issued a final recommendation to reimburse Imfinzi (durvalumab) in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for adults with resectable stage II to IVA gastric or gastroesophageal junction adenocarcinoma — conditional on certain criteria being met.
The oncology counterpart, with a twist that rewards close reading. In April, CDA-AMC issued a final recommendation to reimburse Imfinzi (durvalumab), in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment followed by adjuvant durvalumab monotherapy, for adults with resectable stage II to IVA gastric or gastroesophageal junction adenocarcinoma — if certain conditions are met. The headline is a franchise extension into the resectable, curative-intent setting. The substance is in the phrase "if certain conditions are met."
Create a free account to read the full interpretation.
You’ve reached the part where The Indication earns its name — the read on distribution, reimbursement timing, and channel strategy. It’s free to finish: sign in or create an account to keep reading every analysis in full.